Prelude Therapeutics Incorporated
PRLD · NASDAQ
Bulios Fair Price
$2.94
25.8% downside
Current Price
$3.96
According to Bulios Fair Price, PRLD is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Prelude Therapeutics Incorporated (PRLD) is an American biopharmaceutical company focused on developing drugs for the treatment of cancer and other oncological diseases. Headquartered in Wilmington, Delaware, the company focuses on the discovery and development of small molecule inhibitors targeting specific signaling pathways and cellular mechanisms that are key to the growth and spread of cancer cells. Their research and development efforts are aimed at identifying and developing new drug compounds with the potential to provide new treatment options for cancer patients. Prelude Therapeutics seeks to leverage its deep understanding of the molecular mechanisms of cancer to create innovative therapeutic approaches and drugs with higher efficacy and lower side effects. Prelude Therapeutics Incorporated (PRLD) shares could be an attractive choice for investors following the biopharmaceutical sector and seeking investment opportunities in the research and development of drugs for oncological diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Krishna Vaddi
Employees
79
Headquarters
Wilmington
Upcoming events
Earnings
Upcoming earnings report